Features
Why Choose BONTAC?
Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NAD Drip: Materials, NAD Powder, and Effectiveness Explained
NAD Drip therapy, also known as IV NAD therapy, is gaining attention for its potential health benefits. In this comprehensive guide, we delve into the essential components of NAD Drip, including the standards for NAD drip materials, the role of NAD powder in the process, and its effectiveness in promoting overall well-being.
- NAD Drip Materials Standards
- Quality Assurance in Material Selection:
For an effective NAD Drip, ensuring the highest standards in material selection is paramount. IV bags, tubing, and other equipment must meet stringent quality standards to guarantee patient safety and the proper administration of NAD.
- Sterilization and Safety Protocols:
Safety protocols, including sterilization, must be rigorously maintained. The materials involved in the NAD Drip process should adhere to industry best practices for cleanliness and patient safety.
- Professional Administration:
Trained healthcare professionals are essential for administering NAD Drip safely and effectively. Adequate training and certification of personnel are part of the materials standard.
- NAD Powder in NAD Drip
- The Role of NAD Powder:
NAD (Nicotinamide Adenine Dinucleotide) powder is a crucial component of NAD Drip therapy. It is a bioavailable form of NAD that is dissolved in a sterile saline solution for intravenous infusion.
- Purity and Quality:
The quality and purity of NAD powder are vital. The best NAD powder is produced using high-quality raw materials and rigorous manufacturing standards to ensure the absence of impurities or contaminants.
- Dosage and Customization:
NAD Drip therapy can be tailored to individual needs through the precise control of NAD powder dosage. Customized dosages can be formulated based on a patient's specific requirements.
- NAD Drip Effectiveness
- Boosting Cellular Energy:
NAD Drip therapy is believed to enhance cellular energy production by increasing NAD levels in the body. This has potential benefits for overall vitality and performance.
- Anti-Aging Properties:
NAD Drip therapy is also associated with potential anti-aging effects, as NAD plays a key role in DNA repair and cell rejuvenation.
- Support for Wellness:
Many individuals turn to NAD Drip therapy to support general wellness, particularly in conditions related to fatigue, oxidative stress, and age-related health concerns.
NAD Drip therapy is a promising avenue for those seeking to optimize their well-being. Ensuring the highest standards for NAD Drip materials, the quality of NAD powder, and understanding its potential effectiveness is essential for a safe and successful therapy experience.
Featured Products
Collection about BONTAC
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
Our updates and blog posts
Maternal NAD Precursor Supplementation to Reduce the Risk of Developing CNDD
1. Introduction Nicotinamide adenine dinucleotide (NAD) has been unveiled to be essential for embryonic development. Patients with genetic variants in the NAD+ de novo synthesis pathway often have congenital NAD deficiency disorder (CNDD), a multisystem condition inherited in an autosomal recessive manner. In the context of NAD+ deficiency, all organs and systems, not just vertebrae, heart, kidneys, and limbs, may be affected. 2. The association between NAD synthetase 1 (NADSYN1) and CNDD Individuals delivering biallelic NADSYN1 variants share similar clinical features to those with CNDD. Up till now, almost all of the identified CNDD cases can be attributed to biallelic loss-of-function variants in any of 3 nonredundant genes of the NAD de novo synthesis pathway, including kynureninase (KYNU), 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), or NADSYN1. Among individuals with CNDD identified to date, those with biallelic pathogenic NADSYN1 variants are the most diverse in phenotype. 3. The impact of NADSYN1 variants upon enzymatic activity and phenotype Specifically, NADSYN1 can catalyse the amidation of nicotinic acid adenine dinucleotide (NaAD) to NAD. Biallelic pathogenic variants in NADSYN1 cause a metabolic block in both the de novo pathway and the Preiss-Handler pathway, leading to NAD deficiency. Biallelic NADSYN1 loss-of-function variants impact the NAD metabolome of humans. Post-birth phenotypes involve feeding difficulties, developmental delay, short stature, etc. 4. Mouse embryogenesis disrupted by the loss of NADSYN1 In NADSYN1-/- mouse embryos, NAD-dependent malformations occur when maternal dietary NAD precursors are limited during gestation. The affected Nadsyn1-/- embryos most frequently present malformations of the kidneys, eyes, and lungs. 5. The preventative effect of amidated NAD precursor supplementation against CNDD NADSYN1-dependent embryo loss and malformation in mice are preventable by dietary supplementation of amidated NAD precursors (NMN and NAM) during pregnancy. Maternal diet–derived NAD precursors primarily determine the development of healthy embryos. 6. Conclusion NAD-boosting supplements are essential for individuals with biallelic loss-of-function variants in NADSYN1. Maternal NAD precursor supplementation, to some extent, can reduce the risk of developing CNDD. Reference Szot JO, Cuny H, Martin EM, et al. A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder. J Clin Invest. 2024;134(4):e174824. Published 2024 Feb 15. doi:10.1172/JCI174824 About BONTAC BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR), with various forms to be selected (eg. endoxin-free IVD-grade NAD, Na-free or Na-containing NAD; NR-CL or NR-Malate). High quality and stable supply of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Health Food Expo, Ingredients and Contract Manufacture 2024 is approaching
On April 24th-25th 2024, Health Food Expo, Ingredients and Contract Manufacture 2024 will be held in Tokyo International Exhibition Hall, Japan. Dr Cheung, the chief scientist and founder of BONTAC, is invited to deliver a speech themed by Independent Wholechain Technology for Coenzyme Synthesis at this exhibition. BONTAC will display patent-grade raw materials for enzymes and natural products at Booth No. A15. See you there for more surprises! About Dr. Cheung Dr Cheung, the chief scientist and founder of BONTAC, was once engaged in research work at the Institute of Genetics and Developmental Biology in Chinese Academy of Sciences, Cornell University and City University of Hong Kong. She has been dedicated to the application of biological enzyme catalysis technology into the green bio-manufacturing industrialization of coenzymes, medical intermediates and natural products for over 20 years. Notably, Dr. Cheung has applied approximately 90 invention patents at home and abroad, authorized over 60 patents and conducted key R&D plan projects in Guangdong province as well as key science and technology projects in Shenzhen city. BONTAC Product List Niche Area Products Application Scope NMN (CAS No.: 1094-61-7) Healthcare products; Cosmetics; Medicine NAD (CAS No.: 53-84-9) Healthcare products; Cosmetics; Diagnostic reagents Raw materials for enzyme catalysis; Animal health Coenzyme Endotoxin-free grade NADH (CAS No.: 606-68-98) Functional food and drink; Biomedical research and development Healthcare product; Diagnostic reagents NADP (CAS No.: 24292-60-2/1184-16-3) Raw materials for medicine or enzyme catalysis; Diagnostic reagents; In vitro diagnostic reagents (GR); Biomedical research and development S-NAD (CAS No.: 4090-29-3) Biochemical diagnostic reagents NR (CAS No.: 23111-00-4) Healthcare products; Cosmetics; Diagnostic reagent Natural products Ginsenoside Rh2(CAS No.：78214-33-2) Healthcare products; Cosmetics; Drink; Alcohol; Medicine; Functional food Ginsenoside Rg3(Cas No. : 38243-03-7) Salidroside (Cas No.: 10338-51-9) Healthcare products; Scientific research experiment; New drug development Stevia Sweetener (RD)(Cas No.: 63279-13-0 ) Food; Drink; Daily chemical industry; Brewing Raw materials for cosmetics Pro-Xylane (CAS No.: 439685-79-7) Cosmetics Erythrothioneine Cosmetics Dietary supplements L-Glutathione Reduced Healthcare products; Cosmetics Resveratrol Healthcare products; Cosmetics Phosphatidylserine Healthcare products; Biochemical diagnostic reagent Medicine and intermediate Ursodeoxycholic acid(CAS No.: 128-13-2) Healthcare products; Biochemical diagnostic reagent Chenodeoxycholic acid Healthcare products; Biochemical diagnostic reagent Cholic acid Healthcare products; Biochemical diagnostic reagents BONTAC profile Bontac Bio-Engineering (Shenzhen) Co., Ltd. (also referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales. There are six major series of product in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates. BONTAC is the pioneer of NMN industry. By virtue of the first whole-enzyme catalysis technology in China, BONTAC takes the industry lead in its niche field of coenzyme. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents.
Improvement of Rheumatoid Arthritis Via MSCs-Exo in Combination With Rh2
Introduction In light of a statistics report by World Health Organization (WHO), there are 18 million people suffering from rheumatoid arthritis (RA) worldwide in 2019, where the prevalence of female is 2.5 times that of male. This disorder greatly affects the life quality of patients and even causes disability in severe case. Noteworthily, mesenchymal stem cell-derived exosome (MSCs-exo) in combination with ginsenoside Rh2 has been unveiled to be effective in alleviating RA symptoms, holding a great promise as an adjuvant drug for RA. About RA RA represents a chronic autoimmune disease generally occurring in middle age, which is chiefly featured by vascular proliferation, synovium inflammation and the stiffness/swelling/deformation/pain of one or more joints. At present, the treatment of RA relies on corticosteroids, nonsteroidal anti-inflammatory drugs, synthetic disease-modifying anti-rheumatic drugs, and biological agents. Yet, long-term use of these drugs may be accompanied with various adverse effects such as infection, liver damage, gastrointestinal damage, and heart failure. MSCs vs. MSCs-exo MSCs, with multiple differentiation potential, can reduce joint inflammation in RA. Nevertheless, there are potential risks such as immunogenicity, heterogeneity of different batches of cells, tumorigenicity, and ethical issues, limiting the application of MSCs. MSCs-exo is small extracellular vesicle secreted by MSCs, whose diameter ranges from 30 to 150 nanometers. It can carry biologically active substances such as nucleic acids and small molecules, fulfilling the function of MSCs. Relative to MSCs, MSCs-exo has low immunogenicity and has no risk of tumor formation and ethical constraints. Research protocol A collagen-induced arthritis (CIA) model is constructed in rats, followed by the treatment of phosphate-buffered saline or single/combined therapy of MSCs-exo and ginsenoside Rh2. The rat fences are collected for 16 rRNA amplification sequencing and untargeted metabolomics analysis. Significant efficacy of MSCs-exo combined with ginsenoside Rh2 in RA The combined therapy of MSCs-exo and ginsenoside Rh2, to a large extent, ameliorates RA symptoms in CIA model rats, as manifested by the reduction of joint swelling as well as significant decline in arthritis score and paw thickness. Meanwhile, the histopathological changes in CIA model rats are apparently improved. Rh2 enhances the ability of MSC-exo to suppress the expression of inflammatory factors in synovium and cartilage of CIA model rats, as evidenced by the downregulation of TNF-α, IL-1β and IL-6 as well as upregulation of IL-10 in exo+Rh2 group. Besides, bone erosion in the ankle joints of CIA rats is improved, as attested by the obvious increases in BMD and Tb.Th, as well as prominent decreases in BS/BV and Tb.Sp in exo+Rh2 group. Essential role of gut-joint axis in RA Gut microbiota and metabolites have been deemed to be critical in developing RA. Strikingly, MSCs-exo and Rh2 can significantly ameliorate the disturbed gut microbiota in CIA model rats. The regulation of Candidatus_Saccharibacteria and Clostridium_XlVb may be the most pivotal. Concretely, Candidatus_Saccharibacteria modulates the metabolic pathway of vitamin digestion and absorption by pantothenic acid and vitamin D3 alterations. As for Clostridium_XlVb, it regulates 16(R)-HETE alterations in the arachidonic acid metabolic pathway. Conclusion MSCs-exo and Rh2 act synergistically to ameliorate RA by modulating the gut microbiota and metabolites, especially the reshaping of Candidatus_Saccharibacteria and Clostridium_XlVb abundance. Reference Zhou Z, Li Y, Wu S, et al. Host-microbiota interactions in collagen-induced arthritis rats treated with human umbilical cord mesenchymal stem cell exosome and ginsenoside Rh2. Biomed Pharmacother. Published online April 2, 2024. doi:10.1016/j.biopha.2024.116515 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible or liable in any way for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.